ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2031

Conditions
Corneal Transplant Failure
Interventions
PROCEDURE

Corneal Donor Tissue with Cross Linking

Participants are transplanted with corneal donor tissue that has been treated with 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous \& Photrexa®) with UV light treatment.

PROCEDURE

Corneal Donor Tissue without Cross Linking

Participants are transplanted with corneal donor tissue that has not been treated with the UV light and the 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous \& Photrexa®) without UV light treatment, this is the control group.

Trial Locations (10)

27006

NOT_YET_RECRUITING

Wake Forest Baptist Eye Center, Bermuda Run

27705

NOT_YET_RECRUITING

Duke University - Duke Eye Center, Durham

33136

RECRUITING

University of Miami - Bascom Palmer Eye Institute, Miami

45242

RECRUITING

Cincinnati Eye Institute, Cincinnati

46260

RECRUITING

Price Vision Group, Indianapolis

48015

NOT_YET_RECRUITING

University of Michigan - Kellogg Eye Center, Ann Arbor

90095

NOT_YET_RECRUITING

The University of California Los Angeles - Doris Stein Eye Research Center, Los Angeles

92617

NOT_YET_RECRUITING

University of California Irvine - Gavin Herbert Eye Institute, Irvine

94158

NOT_YET_RECRUITING

University of California San Francisco - Wayne and Gladys Valley Center for Vision, San Francisco

02114

RECRUITING

Massachusetts Eye and Ear, Boston

All Listed Sponsors
lead

Massachusetts Eye and Ear Infirmary

OTHER